Zoledronic acid increases spine bone mass and prevents hip bone loss after bariatric surgery: a randomized placebo‐controlled study
Primary result · Spine vBMDResult — go to the resultEstimated mean treatment effect 6.8 mg/cm³ 95% CI 1.9–11.7Authors' conclusion
Zoledronic acid increases bone mass in the spine and prevents bone loss in the hip region after bariatric surgery compared with placebo.
Study context
- Population
- Patients undergoing RYGB or SG; mean (SD) age 48.9 (6.3) years, BMI 42.3 (5.3), 73% femalerandomized 1:1
- Participants
- 59 patients
- Comparison
- Preoperative zoledronic acid 5 mg vs placebo
- Primary endpoint
- Change in spine volumetric BMD (vBMD)
- Follow-up
- 12 months after surgery
Methodological detailsdouble-blinded, placebo-controlled
- Double-blinded
- Placebo-controlled
Primary result
Spine vBMD · 12 months
Estimated mean treatment effect
6.8 mg/cm³
95% CI 1.9–11.7
P = 0.003
By group
INT
2.6%
As reported in the abstract
Secondary outcomes
| Outcome | INT | CON | Estimated mean treatment effect (mg/cm³) (95% CI) | P value |
|---|---|---|---|---|
| Total hip vBMD | −0.6% | −3.6% | 5.0 (1.4–8.5) | P = 0.006 |
Total hip volumetric bone mineral density (vBMD)
- Bone loss in total hip prevented in INT vs CON
Original publication
Zoledronic acid increases spine bone mass and prevents hip bone loss after bariatric surgery: a randomized placebo‐controlled study. Obesity (Silver Spring). Published 20 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →